Cardiol Therapeutics (TSE:CRDL) Reaches New 52-Week High – Still a Buy?

Cardiol Therapeutics Inc. (TSE:CRDL)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as C$2.70 and last traded at C$2.62, with a volume of 142495 shares. The stock had previously closed at C$2.61.

Cardiol Therapeutics Price Performance

The company has a market cap of C$302.01 million, a price-to-earnings ratio of -7.71 and a beta of 0.27. The company has a quick ratio of 6.84, a current ratio of 5.55 and a debt-to-equity ratio of 0.45. The company has a fifty day simple moving average of C$1.71 and a two-hundred day simple moving average of C$1.66.

Cardiol Therapeutics (TSE:CRDL) last announced its quarterly earnings data on Wednesday, August 12th. The company reported C($0.05) earnings per share (EPS) for the quarter. On average, equities research analysts anticipate that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current fiscal year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.